

CITATION REPORT

List of articles citing

Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome

DOI: 10.1016/j.mayocp.2017.05.010
Mayo Clinic Proceedings, 2017, 92, 1118-1128.

Source: <https://exaly.com/paper-pdf/67503946/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
70	Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. <i>Leukemia Research</i> , 2018 , 66, 89-95	2.7	4
69	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018 , 32, 1200-1210	10.7	68
68	Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. <i>Wiener Klinische Wochenschrift</i> , 2018 , 130, 126-133	2.3	13
67	Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis. <i>Acta Haematologica</i> , 2018 , 139, 164-165	2.7	3
66	Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm. <i>Acta Haematologica</i> , 2018 , 140, 231-233	2.7	4
65	MPN: Next Questions Understanding Fibrotic and Leukemic Transformation of MPN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, S43-S44	2	
64	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. <i>Blood Advances</i> , 2018 , 2, 370-380	7.8	55
63	Downregulation of RPN2 induces apoptosis and inhibits migration and invasion in colon carcinoma. <i>Oncology Reports</i> , 2018 , 40, 283-293	3.5	16
62	[Retinal manifestation in hematological diseases]. <i>Ophthalmologe</i> , 2018 , 115, 799-812	1.6	2
61	Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes. <i>Journal of Blood Medicine</i> , 2019 , 10, 359-371	2.3	7
60	Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. <i>European Journal of Haematology</i> , 2019 , 103, 597-606	3.8	6
59	Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. <i>Frontiers in Oncology</i> , 2019 , 9, 417	5.3	126
58	Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. <i>Biochemical Pharmacology</i> , 2019 , 167, 133-148	6	14
57	Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?. <i>Best Practice and Research in Clinical Haematology</i> , 2019 , 32, 65-73	4.2	10
56	Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. <i>Blood Advances</i> , 2019 , 3, 3700-3708	7.8	13
55	Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. <i>American Journal of Hematology</i> , 2019 , 94, 62-73	7.1	6
54	Thrombocytosis: Perioperative Considerations for Patients Undergoing Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020 , 34, 772-781	2.1	0

53	Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. <i>International Journal of Hematology</i> , 2020 , 111, 182-191	2.3	9
52	Use of molecular mutations in high risk MPN for assessment of blastic transformation. <i>Pathology</i> , 2020 , 52, S113	1.6	
51	Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. <i>Blood Advances</i> , 2020 , 4, 5336-5342	7.8	18
50	Polycythemia Vera Evolution to Chronic Myelomocytic Leukemia: The Prognostic Value of Next Generation Sequencing. <i>HemaSphere</i> , 2020 , 4, e466	0.3	3
49	Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. <i>Cells</i> , 2020 , 9,	7.9	7
48	Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 10978-10986	5.6	14
47	Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms. <i>Expert Review of Hematology</i> , 2020 , 13, 1349-1359	2.8	0
46	Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults. <i>Current Hematologic Malignancy Reports</i> , 2020 , 15, 141-148	4.4	3
45	Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. <i>Genes</i> , 2020 , 11,	4.2	11
44	Unknown unknowns: Limitations in detecting type ii antithrombin deficiency by the XA-based chromogenic method. <i>Pathology</i> , 2020 , 52, S112-S113	1.6	
43	Blood group exome sequencing defines null and weak kidd (JK) Phenotypes: Evidence for transfusion management. <i>Pathology</i> , 2020 , 52, S113	1.6	
42	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1160-1170	4.7	4
41	Bone marrow niche dysregulation in myeloproliferative neoplasms. <i>Haematologica</i> , 2020 , 105, 1189-1200	6.6	9
40	Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. <i>Leukemia</i> , 2021 , 35, 1-17	10.7	47
39	Is there a gender effect in polycythemia vera?. <i>Annals of Hematology</i> , 2021 , 100, 11-25	3	4
38	Accelerated Phase of Myeloproliferative Neoplasms. <i>Acta Haematologica</i> , 2021 , 144, 484-499	2.7	9
37	Thrombocytopenia: Perioperative Considerations for Patients Undergoing Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021 ,	2.1	0
36	Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature. <i>Blood Advances</i> , 2021 , 5, 1059-1068	7.8	3

35	Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. <i>British Journal of Haematology</i> , 2021 , 193, 1004-1008	4.5	2
34	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021 , 96, 781-789	7.1	17
33	Emerging agents and regimens for polycythemia vera and essential thrombocythemia. <i>Biomarker Research</i> , 2021 , 9, 40	8	3
32	Transformation of Polycythemia Vera to Pure Erythroid Leukemia. <i>Cureus</i> , 2021 , 13, e16168	1.2	
31	3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. <i>Current Oncology Reports</i> , 2021 , 23, 120	6.3	2
30	The Tyrosine Kinase-Driven Networks of Novel Long Non-coding RNAs and Their Molecular Targets in Myeloproliferative Neoplasms. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 643043	5.7	1
29	Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells. <i>Gene Therapy</i> , 2021 ,	4	1
28	Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. <i>Blood Reviews</i> , 2020 , 42, 100706	11.1	26
27	The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases. <i>Ecancermedicalscience</i> , 2020 , 14, 1011	2.7	1
26	Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome. <i>Korean Journal of Internal Medicine</i> , 2020 , 35, 457-464	2.5	8
25	The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies. <i>Balkan Medical Journal</i> , 2019 , 36, 78-87	1.5	2
24	SPECTRUM OF AFFECTED GENES IN UKRAINIAN PATIENTS WITH PRIMARY MYELOFIBROSIS. <i>Bulletin of Problems Biology and Medicine</i> , 2018 , 2, 204	0.1	
23	Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF).. <i>Leukemia and Lymphoma</i> , 2022 , 1-3	1.9	
22	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.. <i>International Review of Cell and Molecular Biology</i> , 2022 , 366, 83-124	6	2
21	Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. <i>American Journal of Blood Research</i> , 2021 , 11, 472-497	1.6	0
20	Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.. <i>Blood Reviews</i> , 2022 , 100947	11.1	1
19	promoter hypermethylation as a biomarker for the leukemic transformation of myeloproliferative neoplasms.. <i>Epigenomics</i> , 2022 ,	4.4	1
18	Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.. <i>Nature Communications</i> , 2022 , 13, 1750	17.4	0

17	Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing.. <i>Cells</i> , 2021 , 11,	7.9	2
16	Philadelphia-positive acute lymphoblastic leukemia in a case of MPL p.(W515L) variant essential thrombocythemia: case report and literature review.. <i>Platelets</i> , 2021 , 1-6	3.6	
15	Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms.. <i>Internal Medicine</i> , 2022 ,	1.1	
14	Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.		
13	Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations.		0
12	Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study. 1-6		1
11	Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital. Volume 13, 495-503		0
10	The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Myeloproliferative Neoplasms.		2
9	HOXA9 has the hallmarks of a biological switch with implications in blood cancers. 2022 , 13,		0
8	Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective. 2022 , 23, 15256		0
7	Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis. 2023 , 55, 348-360		0
6	International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. 2023 , 482, 53-68		2
5	Blast phase myeloproliferative neoplasm: Transplant to the rescue.		0
4	Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. 2023 , 98, 801-821		0
3	Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms. 1-20		0
2	Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms. 1-9		0
1	Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis. 2023 , 15, 1785		0